

Paula Rovira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8223681/publications.pdf>

Version: 2024-02-01

28
papers

1,349
citations

759233

12
h-index

752698

20
g-index

32
all docs

32
docs citations

32
times ranked

3304
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. <i>Cell</i> , 2019, 179, 1469-1482.e11.	28.9	935
2	Shared genetic background between children and adults with attention deficit/hyperactivity disorder. <i>Neuropsychopharmacology</i> , 2020, 45, 1617-1626.	5.4	72
3	Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality. <i>Molecular Psychiatry</i> , 2020, 25, 2493-2503.	7.9	59
4	Structural brain imaging studies offer clues about the effects of the shared genetic etiology among neuropsychiatric disorders. <i>Molecular Psychiatry</i> , 2021, 26, 2101-2110.	7.9	53
5	Epigenetic signature for attention-deficit/hyperactivity disorder: identification of miR-26b-5p, miR-185-5p, and miR-191-5p as potential biomarkers in peripheral blood mononuclear cells. <i>Neuropsychopharmacology</i> , 2019, 44, 890-897.	5.4	31
6	Genetic association study of childhood aggression across raters, instruments, and age. <i>Translational Psychiatry</i> , 2021, 11, 413.	4.8	31
7	Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder. <i>Nature Communications</i> , 2021, 12, 576.	12.8	28
8	Genetic overlap and causality between substance use disorder and <scp>attentionâ€deficit</scp> and hyperactivity disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2021, 186, 140-150.	1.7	25
9	Meta-analysis and systematic review of ADGRL3 (LPHN3) polymorphisms in ADHD susceptibility. <i>Molecular Psychiatry</i> , 2021, 26, 2277-2285.	7.9	22
10	Associations of major depressive disorder with chronic physical conditions, obesity and medication use: Results from the PISMA-ep study. <i>European Psychiatry</i> , 2019, 60, 20-27.	0.2	19
11	Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder. <i>Scientific Reports</i> , 2018, 8, 1881.	3.3	14
12	Epigenome-wide association study of attention-deficit/hyperactivity disorder in adults. <i>Translational Psychiatry</i> , 2020, 10, 199.	4.8	14
13	Mendelian randomization analysis for attention deficit/hyperactivity disorder: studying a broad range of exposures and outcomes. <i>International Journal of Epidemiology</i> , 2023, 52, 386-402.	1.9	13
14	Gene-wide Association Study Reveals RNF122 Ubiquitin Ligase as a Novel Susceptibility Gene for Attention Deficit Hyperactivity Disorder. <i>Scientific Reports</i> , 2017, 7, 5407.	3.3	11
15	Transcriptome profiling in adult attention-deficit hyperactivity disorder. <i>European Neuropsychopharmacology</i> , 2020, 41, 160-166.	0.7	7
16	Genome-wide analysis of emotional lability in adult attention deficit hyperactivity disorder (ADHD). <i>European Neuropsychopharmacology</i> , 2019, 29, 795-802.	0.7	6
17	Toxoplasma gondii Seropositivity Interacts with Catechol-O-methyltransferase Val105/158Met Variation Increasing the Risk of Schizophrenia. <i>Genes</i> , 2022, 13, 1088.	2.4	3
18	The VAL66MET Bdnf Genetic Polymorphism Does Not Modify The Association Between Major Depression And Body Mass Index (BMI). <i>European Neuropsychopharmacology</i> , 2017, 27, S447.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Comorbid Medical Conditions In Individuals With Major Psychiatric Disorders. European Neuropsychopharmacology, 2017, 27, S396-S397.	0.7	1
20	6.63 CHILDHOOD MALTREATMENT CORRELATES WITH EMOTIONAL LABILITY SYMPTOMS IN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, S224-S225.	0.5	0
21	70GENETIC INFLUENCES CONTRIBUTING TO ATTENTION-DEFICIT/HYPERACTIVITY DISORDER ACROSS THE LIFESPAN: EVIDENCE FROM GENOME-WIDE ASSOCIATION STUDIES. European Neuropsychopharmacology, 2019, 29, S1107-S1108.	0.7	0
22	T2TRANSCRIPTIONAL RISK SCORE (TRS) FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER. European Neuropsychopharmacology, 2019, 29, S221.	0.7	0
23	T5THE USE OF PRS ANALYSIS TO VALIDATE THE PARTIAL ADHD SYNDROME. European Neuropsychopharmacology, 2019, 29, S222.	0.7	0
24	48. A Polygenic Score for Course of Illness in ADHD. Biological Psychiatry, 2019, 85, S20.	1.3	0
25	A GENETIC RISK SCORE, DEPRESSION AND OBESITY: EVIDENCE FROM THE SPANISH POPULATION STUDY PISMA-EP. European Neuropsychopharmacology, 2019, 29, S973.	0.7	0
26	INTEGRATIVE GENOMIC ANALYSIS OF METHYLPHENIDATE RESPONSE IN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER. European Neuropsychopharmacology, 2019, 29, S1002.	0.7	0
27	F5EPIGENETIC SIGNATURE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER: IDENTIFICATION OF MIR-23A-5P, MIR-26B-5P, MIR-185-5P AND MIR-191-5P AS A POTENTIAL BIOMARKER IN PERIPHERAL BLOOD MONONUCLEAR CELLS. European Neuropsychopharmacology, 2019, 29, S1112.	0.7	0
28	CONVERGENT FUNCTIONAL GENOMICS APPROACH TO IDENTIFY GENES INVOLVED IN ATTENTION DEFICIT/HYPERACTIVITY DISORDER. European Neuropsychopharmacology, 2019, 29, S824-S825.	0.7	0